Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2018

View Archived Issues

Study points to new bone building strategy

Oncobiologics begins first clinical trial for ONS-5010 in wet AMD

Codexis announces topline results from phase Ia study of CDX-6114

Myonexus Therapeutics initiates study of first-ever gene therapy for beta-sarcoglycanopathy

Cell-combination delivery of anti-PD-1 antibody induces potent antileukemia responses in mice

Aquinnah Pharmaceuticals divulges new TDP-43 aggregation inhibitors

Neurocrine Biosciences presents SLC18A2 inhibitors

In situ delivery and retention of cytotoxic drugs with AvidinOX improve their antitumor efficacy

Neurotensin (8-13) analogue demonstrates anxiolytic potential in chronic pain models

Takeda Pharmaceutical presents first preclinical results for LSD1 inhibitor T-448

Activated mesenchymal stem cells show robust preclinical results for treating ischemic stroke

Neurotensin type 1 receptor pepducin PP-001 shows analgesic activity in vivo

Tempest Therapeutics discloses prostanoid EP4 receptor antagonists

Gene therapy based on newly discovered EBP50 mutation improves neuropathy

EA Pharma signs joint research agreement to advance E-6011 for Crohn's disease

Palatin reports first-in-human data on subcutaneous dosing with MC1 receptor agonist peptide PL-8177

Innovent presents data on sintilimab in first-line squamous NSCLC

Cue Biopharma and LG Chem collaborate to develop Immuno-STAT biologics for cancer

European Commission approves expanded label for Trelegy Ellipta in COPD

Chemokine receptor 8 identified as a marker of ANCA-negative ANCA-associated vasculitis

Inhibiting N-glycase-1 increases the efficacy of chemotherapy in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...